NEWS
03 March 2010
Encorium Vaccine Core Team is present at World Vaccine Congress Washington DC on 19th – 22nd of April 2010
Please visit our Vaccine page at: www.encorium.com/vaccines

05 February 2010
Encorium receives French Research Tax
Credit approval
The French Ministry for Higher Education and
Research has approved Encorium’s application to conduct R&D
activities on behalf of private companies.
This approval allows companies subject to the French General Tax
Code to take advantage of the research and development tax credit
offered by France. As a result, Encorium’s current and future French
customers will be able to benefit from the CIR from 2009 to 2011 by
which time the approval is up for renewal.
Research and Development (R&D) tax credits have emerged as one
of the preferred tools for promoting and expanding R&D spending. In
France the pharmaceuticals industry benefits from one of the best
R&D tax-credit system in Europe, which reimburses up to 50% of
R&D costs in the first year.
Dr. Kai Lindevall, CEO stated, “We are delighted to announce that
our application has been successful. This approval will help our
existing and future customers to take advantage of the R&D tax
credit enabling them to invest more money into the development of their
products. This is yet another example of Encorium’s recognition as a
high quality CRO and will further strengthen our market position in
France.”
>
Printer
version 

19 Oct 2009
Encorium Group, Inc. Completes $1.6
Million Private Placement of Common Stock and Executes Warrant Exchange
Agreement; Ends Discussions to Sell Encorium OY
Encorium Group, Inc. (Nasdaq:
ENCO), a full service multinational clinical research
organization (CRO) that provides design, development, and management
capabilities for clinical trials and patient registries to
many of the world's leading pharmaceutical companies, today announced
that it has completed a private placement of 3,937,500 shares of its
common stock with a private investor for an aggregate purchase price of
$1,575,000, or $.40 per share.
Prior to the transaction, the Company has
entered into Warrant Exchange Agreements with two investors (the
"Investors") pursuant to which the Company issued to the Investors an
aggregate of 1,864,000 shares of Common Stock (collectively, the
"Exchange Shares") and warrants to purchase an aggregate of 874,126
shares of Common Stock, exercisable for a period of five years, at an
exercise price of $.40 per share (collectively, the "Exchange
Warrants"). The Exchange Shares and Exchange Warrants were issued in
exchange for warrants dated as of May 9, 2007 held by the Investors to
purchase an aggregate of 874,126 shares of Common Stock of the Company
(collectively, the "Original Warrants").
The Company also announced that it has terminated previously announced
negotiations for the sale of the Company’s wholly-owned subsidiary
Encorium OY to a clinical research organization based in the United
States and will not pursue a sale of the Company or Encorium OY at this
time. Given the Company’s recent successes with respect to its strategy
to grow into the world's leading vaccine franchise, including the
recently announced $8.7 million of new business contract wins and the
selection by a major pharmaceutical company for participation in a
swine flu vaccine program, together with the investment announced
today, the Company believes it is well positioned to win future
contracts in the vaccine and oncology fields. As a result, the Company
believes stockholder value will be maximized by moving ahead
independently, while continuing to focus on clinical vaccine
development.
Dr. Kai Lindevall, executive chairman stated, “We are very pleased that
we were able to close this financing to shore up our balance sheet and
provide the Company with additional working capital. Our experience and
capabilities in the vaccine field coupled with the recent new awards in
this area demonstrate the long term potential we have to grow into a
leading vaccine franchise with expertise in pre-clinical support,
regulatory consultancy and strategic trial planning. We believe these
developments will position us to move ahead independently and are in
the best interest of all stockholders.”
>
Printer
version 

09 Sep 2009
Encorium Group, Inc. Announces New
Business Awards of $8.7 Million, Including Swine Flu (Influenza A H1N1
virus) Vaccine Trial Win
Company Successful with its Strategic Focus
on Vaccines and Oncology Trials
Encorium today announced the signing of
approximately $8.7 million of new business contracts, including
selection by a major pharmaceutical company for participation in a
swine flu vaccine program.
Dr. Kai Lindevall, executive chairman
stated, “We are delighted to be able to announce these new business
awards, despite a very challenging market environment. Our experience
and capabilities in the vaccine field have been of paramount importance
in our success. We are very proud of being the selected partner for one
of the frontline clinical development programs for the swine flu
vaccine. In addition, we were also recently entrusted with a avian flue
vaccine, as well as other vaccine development programs having, in the
aggregate, approximately 12,000 patient subjects. We believe our
participation in these studies exemplifies the level of trust and
respect that large vaccine companies have in our vaccine expertise and
clinical operations.
“We believe Encorium has developed into one
of the strongest medium sized clinical research organizations with
expertise in the field of clinical vaccine development. Our recent
success in the vaccine field has been substantial, with revenues from
vaccine trials increasing by 150% in 2009 versus 2008. As an
acknowledgement of our achievements, in April 2009, Encorium was
nominated as a finalist for the Second Annual Vaccine Industry
Excellence Award.
“The establishment of our Core Vaccine Team
has made it possible to enter strategic partnerships with a number of
clients. Moving forward, our goal is to grow into the world’s leading
vaccine franchise and to create a vertical niche expertise in the field
of vaccine research, covering pre-clinical support, regulatory
consultancy and strategic trial planning. As an integral part of this
strategy, the Company has began and plans to continue creating global
investigator and clinic networks to strengthen the Company’s ability to
conduct large scale global phase III vaccine trials. Through these
networks it will be possible for us to achieve fast and efficient
subject/patient recruitment for vaccine trials globally, which will
also ensure a strong local ownership and a strong ethical foundation.
“The Company has also been successful in
winning trials in the field of oncology during 2009. Thus far in 2009,
Oncology trials constitute the second largest revenue generating
therapeutic field after vaccines. We believe our vaccine experience
will continue to assist us in gaining new contract wins in the oncology
sector, as we will continue to focus, not just on prophylactic
vaccines, but also on therapeutic vaccines, which constitute a
substantial number of oncology trials and are the fastest growing area
within vaccine development. Based on our expertise and success in the
field of vaccines and oncology, we believe we are well positioned to
further strengthen our market position in these niche areas.”
The new business awards announced today
mitigate any negative impact to our backlog as reported at June 30,
2009 from foreign currency translations, contract amendments and
terminations and revenue recognized. The Company had reported
consolidated backlog at June 30, 2009 from continuing operations of
$19.6 million which compared to a backlog of $23.5 million at June 30,
2008.
>
Printer
version 

17 Jul 2009
Encorium Group Completes Sale of its
U.S. Business to Pierrel Research USA;
Announces Management Changes
Encorium Group, Inc. (Nasdaq:
ENCO), a full service multinational clinical research
organization (CRO) that provides design, development, and management
capabilities for clinical trials and patient registries to
many of the world's leading pharmaceutical companies, today announced
that is has completed the previously announced sale of
the Company’s U.S. business to Pierrel Research USA, Inc., a
wholly-owned subsidiary of Pierrel SpA, an international contract
research organization listed on Milano’s Stock Exchange. The purchase
price was $2.7 million, comprised of $80,000 in cash as
well as the assumption of $2.6 million in liabilities.
In connection with the consummation of the
sale, Pierrel Research USA has entered into a lease with the landlord
of the
Company’s U.S. headquarters in Wayne, Pennsylvania, pursuant to which
the landlord has agreed to release the Company from its
remaining lease obligations of approximately $3.4 million for a
termination fee of $235,000.
As of the closing of the transaction, Dr.
David Ginsberg, Chief Executive Officer of the Company, has joined
Pierrel Research
USA as its Chief Executive Officer. In addition, Pierrel has extended
employment to substantially all of Encorium’s U.S.
employees. As a result, Pierrel expects that the U.S. operations will
continue largely unchanged and that it will be able to
seamlessly continue to deliver the services our customers depend on.
Encorium has obtained authorizations from its affected
customers allowing the Company to transfer the provision of services to
Pierrel.
Dr. Kai Lindevall, Chairman of the Board and
President of Europe and Asia, commented, "We believe that the sale of
our U.S.
business to Pierrell, a well respected international contact research
organization with a strong management team and therapeutic
and regulatory expertise, is in the best interest of our stockholders,
employees and customers."
In conjunction with the sale of the U.S.
assets, the Company also announced the departure of Linda L. Nardone,
Ph.D., Encorium’s
Chief Operating Officer.
>
Printer
version 

18 June 2009
Encorium Group Provides Update to LOI
with Respect to the Sale of its
U.S. Business
Encorium Group, Inc. (Nasdaq:
ENCO), a
full service multinational contract research organization (CRO) that
provides design, development, and management capabilities for clinical
trials and patient registries to many of the world's leading
pharmaceutical companies, today announced that the Board of Directors
of the Company has approved amended terms to the previously announced
letter of intent with Pierrel SpA, an international contract research
organization listed on Milano’s Stock Exchange, for the sale of its
U.S. business. The sale is expected to close on June 30, 2009.
Subject to the negotiation of a definitive
agreement, pursuant to the
letter of intent, Pierrel has the right to purchase the Company’s U.S.
Line of Business for a purchase price equal 17% of the Company’s U.S.
backlog at closing, less the amount that assumed current liabilities
exceed acquired current assets by more than $500,000, as opposed to
$350,000 as was provided for in the original letter of intent. The
Company anticipates that backlog as of June 30, 2009 will be
approximately $11.5 million. It is estimated that at closing, the
liabilities assumed by Pierrel will exceed the assets transferred by
the Company by more than the $500,000 deficiency allowance. As a
result, the Company does not anticipate it will receive cash from
Pierrel at closing.
>
Printer
version 

18 May 2009
Encorium Group Provides Update to LOI
with Respect to the Sale of its
U.S. Business
Encorium Group,
Inc. (Nasdaq: ENCO), a full service multinational
contract research
organization (CRO) that provides design, development, and management
capabilities for clinical trials and patient registries to many of the
world's leading pharmaceutical companies, today announced that the
initial non-binding letter of intent with respect to its U.S. business
has been terminated and that the Company has entered into another
letter of intent with Pierrel SpA, an international contract research
organization listed on Milano’s Stock Exchange.
Subject to the
negotiation of a definitive agreement, pursuant to the letter of
intent, Pierrel has the right to purchase the U.S. Line of Business for
a purchase price equal to a percentage of the Company’s U.S. backlog
calculated as of the closing or $1.35 million, whichever is greater,
less the amount, if any, that assumed current liabilities, less assumed
current assets exceeds $350,000. In addition to the purchase price
payable at closing, Pierrel will pay Encorium a 10% commission on the
value of any new contract, net of pass-through costs, executed after
the closing date but prior to December 31, 2009, which constitute part
of the Company’s pipeline at closing.
Encorium Group plans to file a
Current Report on Form 8-K with the United States Securities and
Exchange Commission today containing a more detailed description of the
parties’ rights and obligations under the agreement.
>
Printer
version 

11 May 2009
Encorium Group Enters into Non-Binding
Letters of Intent
Reiterates Going Concern Opinion to Comply with NASDAQ Marketplace Rule
4350(b)(1)(B)
Encorium Group, Inc. (Nasdaq:
ENCO), a full service multinational contract research
organization (CRO) that provides design, development, and management
capabilities for clinical trials and patient registries to many of the
world's leading pharmaceutical companies, today announced that it has
entered into two non-binding letters of intent (“LOI”) with respect to
its U.S. business and its wholly owned European subsidiary, Encorium
Oy.
The first LOI involves the sale of the
assets of Encorium Group, Inc., USA, the Company’s U.S.
business. The Company has signed a non-binding LOI with a
full-service internationally based contract research organization for
an undisclosed price.
The second LOI involves the sale of the
Company’s wholly owned subsidiary Encorium Oy. The Company
has signed a non-binding LOI with a leading full-service clinical
research organization based in the United States and with operations
globally
>
Printer
version 

27 Apr 2009
Encorium
Group Signs Approximately $2.0 Million of New Business Contracts
Encorium Group today
announced the signing of approximately $2.0 million of new business
contracts, consisting of both new business contracts and repeat
business to be conducted primarily in Europe. Revenue
recognition will begin in the second quarter of 2009 on a proportional
basis as services are performed on each project. The backlog
of the company was approximately $31.0 million at April 15, 2009.
>
Printer
version 

27 Apr 2009
Encorium
Named as Finalist for the Second Annual
Vaccine Industry Excellence Award
Encorium Group today
announced that the Company was nominated for the Second Annual Vaccine
Industry Excellence Award for Best Contract Research
Organisation. Encorium was one of only seven leading CROs to
be shortlisted for the award.
>
Printer version 

27 Apr 2009
Encorium Reports Fourth
Quarter and Full Year 2008 Financial Results
- New business awards in 2008 total $36.1
million, an increase of 22% over 2007
- Results include non-cash goodwill
impairment charge of $12.5 million for the fourth quarter, $14.4
million for the full year
> Printer version 

27 Jan 2009
Encorium Group Signs $3.1
Million of New Business Contracts Including an Extension of a Current
U.S. Oncology Clinical Trial with a Major Pharmaceutical Company
>
Printer
version 

10 Sep 2008
Encorium Appoints David
Ginsberg President and Chief Executive Officer,
Announces Changes to the Board of Directors
>
Printer
version 

9 Sep 2008
Prologue Acquisition Update
and Termination of Linkcon Business Combination
>
Printer
version

13 Aug 2008
Encorium Group Signs $3.5
Million of New Contracts for Vaccines Clinical Trials
$13.5 Million of New Business Contracts Announced During the Past Three
Weeks
WAYNE, Pa.--(BUSINESS WIRE)-- Encorium Group, Inc. (Nasdaq: ENCO), a
full-service multinational contract research organization (CRO) that
provides design, development, and management capabilities for clinical
trials and patient registries to many of the world's leading
pharmaceutical and biotechnology companies, today announced the signing
of $3.5 million of new business contracts with a global
biopharmaceutical company. These contracts, which cover clinical trials
in the field of vaccines and infectious diseases, will be conducted in
multiple European countries. Services include regulatory submissions,
project management, and field monitoring. Revenue recognition will
begin in the current quarter with the remainder expected to occur on a
proportional performance basis as services are performed on each
project.
Kenneth M. Borow, M.D., Encorium Group’s President and Chief Medical
and Strategic Development Officer, stated, “With the signing of these
contracts, Encorium has announced approximately $13.5 million of new
business during the past three weeks. In aggregate, these new contracts
represent both repeat and new client business and cover a wide array of
therapeutic areas for multiple small as well as large biopharmaceutical
companies. Encorium will provide clinical trial services for these
studies on three continents including North America, Europe, and South
America. We are very encouraged about our company’s ability to win new
business, especially as we move forward with our globalization
efforts.”
Kai Lindevall, M.D., Ph.D., Encorium’s Chief Executive Officer,
commented, “We see these new contracts as additional confirmation of
the strength of our broad-based vaccines franchise. We are one of the
world’s most experienced contract research organizations (CRO) involved
in the development of prophylactic vaccines. This has allowed us to
recently expand our clinical trial service offerings to include
immunotherapy (i.e., therapeutic vaccines), a growing and innovative
approach to the treatment of human disease.”
> Printer version


22 Jul 2008
Encorium Group Signs
Additional New Contracts Valued at $5.0 Million
Approximately $10 Million of New Business Contracts Announced During
the Past Week
WAYNE, Pa.--(BUSINESS WIRE)-- Encorium
Group, Inc. (Nasdaq: ENCO), a full-service multinational contract
research organization (CRO) that provides design, development, and
management capabilities for clinical trials and patient registries to
many of the world's leading pharmaceutical and biotechnology companies,
today announced $5.0 million of new business contracts with several
multinational as well as smaller biopharmaceutical companies. The
therapeutic areas included in these awards are cardiovascular diseases,
oncology, diabetes, and infectious diseases. Services, which will be
provided in both North America and Europe, include medical/scientific
consulting, data management, regulatory affairs, project management,
field monitoring, and medical monitoring/writing. Revenue recognition
for many of these contracts will begin in the current third quarter of
2008 with the remainder expected to occur on a proportional performance
basis as services are performed on each project.
Kenneth M. Borow, M.D., Encorium Group’s President and Chief Medical
and Strategic Development Officer, stated, “Encorium has announced
approximately $10 million of new business contracts during the past
week which has resulted in an increase in our current backlog of signed
contracts to approximately $43 million. We are very encouraged by these
recent developments and remain confident in our ability to continue to
win new business across a wide array of therapeutic areas and
geographies.”
Kai Lindevall, M.D., Ph.D., Encorium’s Chief Executive Officer,
commented, “We feel that the successful signing of new business and
receipt of new requests for proposals are a clear justification of our
recently announced expansion plans. Pharmaceutical and biotechnology
companies are recognizing the value of our potential therapeutic and
geographic capabilities. That is why I am delighted that we are
proceeding with our plans to acquire the oncology-focused CRO Prologue
and merge with Linkcon. We feel that with the addition of Prologue’s
therapeutic expertise and Linkcon’s expanding group of CROs in India,
Latin America and China/Asia, Encorium will be well positioned to win
large multinational CRO contracts that have previously been difficult
to attain.”
> Printer version


17 Jul 2008
Encorium Group Announces $5.1
Million New Business Contract For A Multinational Cardiovascular Trial
Of An Innovative Anti-thrombotic Agent
WAYNE, Pa. Encorium Group, Inc. (Nasdaq: ENCO) today announced the
signing of a contract for $5.1 million with an innovative biotechnology
company for a Phase 2 clinical trial to be conducted by Encorium in
conjunction with our South American partner Estudios Cl�nicos Latino
Am�rica (ECLA). The contract amount includes $170,000 payable under a
letter of intent that was announced previously. The current trial will
assess the efficacy and safety of multiple doses of a new
anti-thrombotic agent in an at-risk patient population with
cardiovascular disease. Encorium will provide full service support,
including consulting on trial design and protocol development, project
and study site management and monitoring, data management,
biostatistical analysis, safety monitoring, and medical writing.
Revenues will be recognized as services are performed on a proportional
performance basis over the life of the contract, beginning in the
current third quarter.
> Printer version


12 Jun 2008
Encorium Group, Inc. Announces
Signing of Letter of Intent to Combine with Linkcon; Expected Expansion
Will Create Global CRO
Company to Conduct Conference Call at 9:00
AM on Thursday, June 12, 2008 to discuss
Direct link:
WEBCAST
Highlights of the Proposed Combination
• Linkcon is in the process of acquiring a series of clinical research
organizations (“CROs”) throughout the world
• Assuming completion of its acquisitions, Linkcon is expected to add
an aggregate of $11 million in net revenue to Encorium on a pro forma
basis
• Encorium separately announced its intent to acquire Prologue Research
International, Inc. (“Prologue”), a clinical research organization that
specializes in a full range of clinical research services for Phase I
through IV clinical trials in oncology and oncology-related studies
• Total combined company is expected to offer greatly enhanced global
capabilities and therapeutic expertise in the North America, Europe and
emerging markets including India, Latin American and China.
• Combined backlog (including Encorium, Linkcon and Prologue) in the
range of $65-70 million expected at closing
WAYNE, Pa.--(BUSINESS WIRE)-- Encorium
Group, Inc. (Nasdaq: ENCO) (“Encorium” or “the Company”), a
full-service multinational CRO that provides design, development, and
management capabilities for clinical trials and patient registries to
many of the world's leading pharmaceutical and biotechnology companies,
today announced that it has entered into a non-binding letter of intent
to combine (“the Business Combination”) with Fine Success Investments,
Ltd., a British Virgin Islands company doing business as Linkcon
(“Linkcon”). Linkcon has acquired or will acquire either prior to or
simultaneously with the proposed business combination with Encorium:
1) a CRO based in India with over 10 years of clinical trial
experience;
2) a CRO operating throughout Latin America, also with over 10 years of
clinical trial experience;
3) a Chinese CRO that holds licenses to conduct clinical trials in the
People's Republic of China and Hong Kong; and
4) a controlling interest in the Chinese company that holds the license
for JK1, a healthcare portal for medical professionals and consumers
promoting the exchange of medical information between China and the
Western world.
This Business Combination is expected to enhance Encorium’s global
profile as a CRO by broadening the Company’s operational services and
therapeutic area offerings into established and emerging
biopharmaceutical markets across multiple continents.
> Printer version


12 Jun 2008
Encorium Group, Inc. Announces
Signing of Letter of Intent to Acquire Prologue Research International,
Inc.
Highlights
• Prologue is a specialty clinical research organization (“CRO”)
focusing on oncology and oncology-related studies. This acquisition
broadens Encorium’s therapeutic area expertise in this very important
and high-growth area of drug/biologics development.
• Prologue’s annual revenue grew at a compounded rate of greater than
30% from 2005 through 2007.
• Prologue has a backlog in excess of $25 million for the fiscal year
ended December 31, 2007.
WAYNE, Pa.--(BUSINESS WIRE)-- Encorium
Group, Inc. (Nasdaq: ENCO) (“Encorium” or “the Company”), a
full-service, multinational CRO that provides design, development, and
management capabilities for clinical trials and patient registries to
many of the world's leading pharmaceutical and biotechnology companies,
today announced that it has entered into a non-binding letter of intent
to acquire Prologue Research International, Inc. (“Prologue”), a CRO
that specializes in a full range of clinical research services for
Phase I through Phase IV clinical trials in oncology and
oncology-related studies.
> Printer version


11 Jun 2008
Encorium Group, Inc. Conference Call To
Discuss Recent Announcements
Thursday, June 12, 2008 - 9:00 AM ET
Direct link:
WEBCAST

31 Mar 2008
Encorium Group, Inc. Announces
$3.2 Million of New Business Contracts for Europe and North America
WAYNE, Pa.--(BUSINESS WIRE)-- Encorium
Group, Inc. (Nasdaq: ENCO), a full-service multinational contract
research organization (CRO) that provides design, development, and
management capabilities for clinical trials and patient registries to
many of the world's leading pharmaceutical and biotechnology companies,
today announced $3.2 million of additional new business contracts for
Europe and North America. The therapeutic areas included in these
awards are oncology, asthma, diabetes, rheumatology, and
immunology/vaccines. Services to be provided include consulting,
regulatory affairs, project management, field monitoring, and medical
monitoring/writing. Revenue recognition for many of these contracts
will begin in the current second quarter of 2008 with the remainder
expected to occur on a proportional performance basis as services are
performed on each project.
> Printer version


15 May 2008
Encorium Group, Inc. 2008 1st
Quarter Financial Results Webcast
Thursday, May 15, 2008 at 11:00 AM ET
Direct link:
WEBCAST

28 Apr 2008
Encorium Group, Inc. expands
its European operations with the opening of an office in the Cologne
area, Germany, Encorium Germany GmbH
WAYNE, PA, April 28, 2008 – Encorium
Group, Inc. (Nasdaq: ENCO) a global clinical research organization
(CRO) specializing in the design and management of complex clinical
trials and Patient Registries for the pharmaceutical, biotechnology and
medical device industries, announces the opening of an office in
Erftstadt, Germany.
Encorium has successfully been operating in
Germany through the last years with regionally located staff and in
order to continue providing our clients with quality in clinical
research we have now established an office in Erftstadt, Germany.
Christine Mohlberg, MSc., has been appointed
as Country Manager for the operations in Germany. Christine brings more
than 10 years experience in clinical research from both the
pharmaceutical and CRO industry. Christine has extensive experience as
a project leader working on a global scale and brings a wealth of
experience in CNS and oncology.
>
printer version 

7 Apr 2008
Encorium Group, Inc. Announces
Additional $2.2 Million of New Business Contracts With Multiple
European and U.S. Biopharmaceutical Companies
WAYNE, PA, April 7, 2008 -- (BUSINESS
WIRE)-- Encorium Group, Inc. (Nasdaq: ENCO), a full-service
multinational contract research organization (CRO) that provides
design, development, and management capabilities for clinical trials
and patient registries to many of the world's leading pharmaceutical
and biotechnology companies, today announced that it has signed
additional new business contracts valued at approximately $2.2 million
with multiple European and U.S. biopharmaceutical companies. The
therapeutic areas included in these awards are oncology, pulmonary
arterial hypertension, infectious diseases, immunology/vaccines, and
women’s health. Services to be provided include consulting, regulatory
affairs, project management, field monitoring, and medical
monitoring/writing. Revenue recognition is expected to occur on a
proportional performance basis as services are performed on each
project.
>
printer version 

31 Mar 2008
Encorium Group, Inc. Announces
$1.6 Million Contract for a Phase 2 Trial of an Innovative
Immunotherapeutic Vaccine for the Treatment of Hypertension
WAYNE, PA, March 31, 2008 -- Encorium
Group, Inc. (Nasdaq: ENCO), a full-service multinational contract
research organization (CRO) that provides design, development, and
management capabilities for clinical trials and patient registries for
many of the world's leading pharmaceutical and biotechnology companies
today announced the signing of a $1.6 million contract with Protherics,
a leading UK biopharmaceutical company, for a Phase 2 trial of its
novel immunotherapeutic vaccine, Angiotensin Therapeutic Vaccine (ATV),
for the treatment of hypertension.
>
printer version 

26 Mar 2008
Encorium Group, Inc. 2007 4th
Quarter Financial Results Webcast
Wednesday, March 26, 2008 at 11:00 AM ET
Direct link:
WEBCAST

21 Feb 2008
Encorium Group, Inc. Announces
Realignment Of Its Senior Management Team To Meet Its Global Growth
Objectives
WAYNE, PA, February 21, 2008 –
Encorium Group, Inc. (Nasdaq: ENCO), in order to more effectively
support its global growth plans, announced that it is realigning the
responsibilities of its senior management team. These changes are
intended to facilitate globalization of Encorium through expansion of
the Company’s worldwide service offerings with a focus on sustained
revenue growth and profitability. Dr. Kenneth M. Borow is currently
President of Encorium Group, Inc as well as Chief Executive Officer. In
order to allow Dr. Borow to focus more of his time on the expansion of
the Company’s Consultancy Services business and its Global Business
Development initiatives, the responsibilities of Chief Executive
Officer have been transferred as of today to Dr. Kai Lindevall,
presently Encorium’s President of Operations for Europe and Asia. Dr.
Borow will remain President of the Company as well as assume the new
position of Chief Medical and Strategic Development Officer.
>
printer version 

18 Jan 2008
Encorium Group, Inc. Announces
$3.4 Million of Awarded New Business Contracts
WAYNE, PA, January 18, 2008 --
Encorium Group, Inc. (Nasdaq: ENCO), a full-service multinational
contract research organization (CRO) that provides design, development,
and management capabilities for clinical trials and patient registries
to many of the world's leading pharmaceutical and biotechnology
companies, today announced it has been awarded new business contracts
with an aggregate value of approximately $3.4 million. The therapeutic
areas included in these awards are oncology, gynecology, respiratory
diseases, and gastroenterology. Services to be provided include project
management, field monitoring, data management, statistics, medical
writing, and quality assurance. Revenue recognition for several of
these contracts began in the fourth quarter of 2007, with the remainder
beginning in the current first quarter of 2008. Revenue recognition
will occur on a proportional performance basis as services are
performed on each project.
Kenneth M. Borow, M.D., President and Chief
Executive Officer for Encorium Group, commented, “In the past two weeks
Encorium has announced $7.1 million of new business awards. These have
been over a wide array of therapeutic areas and have included many
different services that will be provided to our clients. The work
associated with these opportunities will be performed on a
multinational basis.”
>
printer version 

10 Jan 2008
Encorium Group, Inc. Announces
Signing of $1.7 Million in Contracts with Leading International
Biotechnology Company for Clinical Trials in Oncology and Rheumatology
WAYNE, PA, January 10, 2008 --
Encorium Group, Inc. (Nasdaq: ENCO), a full-service multinational
contract research organization (CRO) that provides design, development,
and management capabilities for clinical trials and patient registries
to many of the world's leading pharmaceutical and biotechnology
companies today announced the signing of multiple new contracts with an
aggregate value of approximately $1.7 million. These contracts, which
are with a leading international biotechnology company, are for
regulatory submission services, support of new clinical trials, and
changes-of-scope for existing studies. The therapeutic areas covered in
these contracts are oncology and rheumatology. Revenue recognition
began during the fourth quarter of 2007 and continues on a proportional
performance basis over the life of the contract as services are
performed.
>
printer version 

7 Jan 2008
Encorium Group, Inc. Announces
the Signing of a $2.0 Million Contract for Data Management Services for
a Global Pharmaceutical Company
WAYNE, PA, January 7, 2008 -- Encorium
Group, Inc. (Nasdaq: ENCO), a full-service multinational contract
research organization (CRO) that provides design, development, and
management capabilities for clinical trials and patient registries to
many of the world's leading pharmaceutical and biotechnology companies,
today announced the signing of an extension to an existing contract for
Global Data Management services valued at approximately $2.0 million. A
significant portion of the revenue from this contract extension, which
was signed during the fourth quarter, is expected to be recognized
during the first half of 2008 as services are performed.
>
printer version 

|